MX2009014193A - Preparacion farmaceutica solida que comprende benzazepinas y metodo de produccion de la misma. - Google Patents

Preparacion farmaceutica solida que comprende benzazepinas y metodo de produccion de la misma.

Info

Publication number
MX2009014193A
MX2009014193A MX2009014193A MX2009014193A MX2009014193A MX 2009014193 A MX2009014193 A MX 2009014193A MX 2009014193 A MX2009014193 A MX 2009014193A MX 2009014193 A MX2009014193 A MX 2009014193A MX 2009014193 A MX2009014193 A MX 2009014193A
Authority
MX
Mexico
Prior art keywords
solid preparation
pharmaceutical solid
benzazepines
particle diameter
production method
Prior art date
Application number
MX2009014193A
Other languages
English (en)
Inventor
Shinsuke Nakagawa
Tadashi Mukai
Kai Suzuki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40070798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009014193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2009014193A publication Critical patent/MX2009014193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee una preparación farmacéutica sólida que tiene propiedades de desintegración superiores y excelente solubilidad, resultando en una absorción adecuada de los ingredientes activos a través del tracto gastrointestinal; la preparación farmacéutica sólida de la presente invención comprende: (a) 7-cloro-5-hidroxi-1-[2-metil-4-(2-metilbenzoilamino )benzoil]-2,3,4,5-tetrahidro-1H-benzazepina y/o una sal de la misma, (b) hidroxipropilcelulosa que contiene un grupo hidroxipropoxilo en una cantidad de 50% en peso o mayor; y (c) por lo menos un miembro seleccionado del grupo que consiste en carmelosa, carboximetil almidón de sodio, crospovidona, e hídroxipropilcelulosa de baja sustitución con un diámetro de partícula promedio de 30 mum a 70 mum, y un diámetro de partícula acumulativo de 90% de 100 mum a 200 mum.
MX2009014193A 2007-06-21 2008-06-20 Preparacion farmaceutica solida que comprende benzazepinas y metodo de produccion de la misma. MX2009014193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007163551 2007-06-21
PCT/JP2008/061686 WO2008156217A2 (en) 2007-06-21 2008-06-20 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Publications (1)

Publication Number Publication Date
MX2009014193A true MX2009014193A (es) 2010-01-28

Family

ID=40070798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009014193A MX2009014193A (es) 2007-06-21 2008-06-20 Preparacion farmaceutica solida que comprende benzazepinas y metodo de produccion de la misma.

Country Status (25)

Country Link
US (4) US10905694B2 (es)
EP (1) EP2167046B1 (es)
JP (1) JP5289338B2 (es)
KR (1) KR101526625B1 (es)
CN (3) CN101686941A (es)
AR (1) AR067077A1 (es)
AT (1) ATE489944T1 (es)
AU (1) AU2008264445B2 (es)
BR (1) BRPI0813100A2 (es)
CA (1) CA2689467A1 (es)
CY (1) CY1111939T1 (es)
DE (1) DE602008003816D1 (es)
DK (1) DK2167046T3 (es)
ES (1) ES2354030T3 (es)
HK (1) HK1201719A1 (es)
HR (1) HRP20100676T1 (es)
IL (1) IL202179A (es)
MX (1) MX2009014193A (es)
MY (1) MY147599A (es)
PL (1) PL2167046T3 (es)
PT (1) PT2167046E (es)
RU (1) RU2466717C2 (es)
SI (1) SI2167046T1 (es)
TW (1) TWI405574B (es)
WO (1) WO2008156217A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102552278A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种提高难溶性药物托伐普坦溶出度的药物组合物
CN102228423B (zh) * 2011-06-29 2013-03-06 重庆市庆余堂制药有限公司 托伐普坦口服固体药物组合物及其制备方法
JP6057628B2 (ja) * 2012-09-06 2017-01-11 クリーンケミカル株式会社 人工透析装置のプライミング方法
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
JP6761695B2 (ja) * 2016-08-16 2020-09-30 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース及び固形製剤
JP6838446B2 (ja) * 2017-03-22 2021-03-03 ニプロ株式会社 トルバプタン製剤およびその製造方法
JP7352175B2 (ja) * 2019-12-25 2023-09-28 ニプロ株式会社 トルバプタン製剤
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
WO2022256378A1 (en) 2021-06-02 2022-12-08 Esperion Therapeutics, Inc. Compositions containing and therapies using bempedoic acid and tolvaptan
EP4321154A1 (en) 2022-08-03 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet of tolvaptan and at least one binder processed with spray granulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2071511A (en) * 1934-10-01 1937-02-23 Reed & Carnrick Enteric coating
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
TW430561B (en) 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
JPH09278656A (ja) * 1996-02-05 1997-10-28 Sankyo Co Ltd 経口投与用５α−リダクターゼ阻害製剤及びその製造方法
ES2364145T3 (es) * 1996-11-15 2011-08-25 Ajinomoto Co., Inc. Composición de nateglinida en comprimidos.
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
MXPA03009588A (es) * 2001-04-18 2004-12-06 Nostrum Pharmaceuticals Inc Un recubrimiento novedoso para una composicion farmaceutica de liberacion sostenida.
JP2004026861A (ja) * 2002-06-21 2004-01-29 Shin Etsu Chem Co Ltd 濾過性に優れる水溶性セルロースエーテル及びその選定方法
JP4684545B2 (ja) * 2002-09-26 2011-05-18 大日本住友製薬株式会社 溶出性の良好なイソキサゾール誘導体経口製剤
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
US20060188563A1 (en) * 2003-03-27 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
TW200507882A (en) 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US8158146B2 (en) * 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride

Also Published As

Publication number Publication date
JP2010530355A (ja) 2010-09-09
US20210069207A1 (en) 2021-03-11
PL2167046T3 (pl) 2011-05-31
HRP20100676T1 (hr) 2011-01-31
CN103989644A (zh) 2014-08-20
US20100323006A1 (en) 2010-12-23
SI2167046T1 (sl) 2011-03-31
BRPI0813100A2 (pt) 2014-12-23
AU2008264445B2 (en) 2013-06-27
TW200911270A (en) 2009-03-16
EP2167046B1 (en) 2010-12-01
US10905694B2 (en) 2021-02-02
CY1111939T1 (el) 2015-11-04
KR101526625B1 (ko) 2015-06-05
US20210113582A1 (en) 2021-04-22
ES2354030T3 (es) 2011-03-09
CN101686941A (zh) 2010-03-31
WO2008156217A3 (en) 2009-02-26
KR20100038386A (ko) 2010-04-14
JP5289338B2 (ja) 2013-09-11
AU2008264445A1 (en) 2008-12-24
EP2167046A2 (en) 2010-03-31
MY147599A (en) 2012-12-31
DE602008003816D1 (de) 2011-01-13
RU2010101797A (ru) 2011-07-27
ATE489944T1 (de) 2010-12-15
RU2466717C2 (ru) 2012-11-20
CN103463095A (zh) 2013-12-25
US20230321113A1 (en) 2023-10-12
IL202179A0 (en) 2010-06-16
PT2167046E (pt) 2011-02-10
IL202179A (en) 2012-10-31
HK1201719A1 (en) 2015-09-11
AR067077A1 (es) 2009-09-30
CA2689467A1 (en) 2008-12-24
TWI405574B (zh) 2013-08-21
DK2167046T3 (da) 2011-01-31
WO2008156217A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
MX2009014193A (es) Preparacion farmaceutica solida que comprende benzazepinas y metodo de produccion de la misma.
WO2007048219A3 (en) Sustained drug release composition
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
MX351855B (es) Composicion farmaceutica para liberacion modificada.
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
NZ620879A (en) A novel formulation of indomethacin
CA2611520A1 (en) Method and composition for pharmaceutical product
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
NZ595663A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP2015511635A5 (es)
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
CN105407926A (zh) 口腔贴剂
DK2306982T3 (en) Pharmaceutical compositions of rosuvastatin calcium
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
BR0117147A (pt) preparado de dosagem oral de desintegração instantánea
IL187632A (en) 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
RU2006137329A (ru) Распадающиеся таблетки, содержащие ликарбазепин
WO2003047552A3 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
NZ594669A (en) Oral composition of Vorinostat
TW200616680A (en) Solid medical preparation
SG152285A1 (en) Solid pharmaceutical formulation
AU2012327176A1 (en) Simethicone formulation

Legal Events

Date Code Title Description
FG Grant or registration